155 related articles for article (PubMed ID: 31583720)
1. Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.
Li C; Fan K; Qu Y; Zhai W; Huang A; Sun X; Xing S
J Cell Physiol; 2020 Apr; 235(4):3721-3730. PubMed ID: 31583720
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
[TBL] [Abstract][Full Text] [Related]
3. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
4. SATB1 3'-UTR and lncRNA-UCA1 competitively bind to miR-495-3p and together regulate the proliferation and invasion of gastric cancer.
Sun L; Liu L; Yang J; Li H; Zhang C
J Cell Biochem; 2019 Apr; 120(4):6671-6682. PubMed ID: 30368875
[TBL] [Abstract][Full Text] [Related]
5. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
[TBL] [Abstract][Full Text] [Related]
6. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway.
Zhang Y; Liu Y; Xu X
J Cell Biochem; 2018 Jul; 119(7):6296-6308. PubMed ID: 29663500
[TBL] [Abstract][Full Text] [Related]
8. LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway.
Shi W; Ling L; Li C; Wu R; Zhang M; Shao F; Wang Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1295-1311. PubMed ID: 35792913
[TBL] [Abstract][Full Text] [Related]
9. LncRNA UCA1 inhibits epilepsy and seizure-induced brain injury by regulating miR-495/Nrf2-ARE signal pathway.
Geng JF; Liu X; Zhao HB; Fan WF; Geng JJ; Liu XZ
Int J Biochem Cell Biol; 2018 Jun; 99():133-139. PubMed ID: 29608952
[TBL] [Abstract][Full Text] [Related]
10. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
13. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
14. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
Chen L; Han X; Hu Z; Chen L
Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
[TBL] [Abstract][Full Text] [Related]
15. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
Shi SL; Zhang ZH
Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.
Fang Q; Chen X; Zhi X
Med Sci Monit; 2016 Oct; 22():3506-3513. PubMed ID: 27694794
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-125a attenuates the chemoresistance against ubenimex in non-small cell lung carcinoma via targeting the aminopeptidase N signaling pathway.
Li C; Zhai W; Wan L; Li J; Huang A; Xing S; Fan K
J Cell Biochem; 2020 Feb; 121(2):1716-1727. PubMed ID: 31595566
[TBL] [Abstract][Full Text] [Related]
19. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
